From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO – GI
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in GI
During the poster discussion session on colon and anal cancer, Prof Dr Eric Van Cutsem from the University Hospital Gasthuisberg, Leuven, offered valuable insights that were informative and relevant.
Prof. Dr Anne Demols presented the latest findings from several studies on gastric, pancreatic, and hepatobiliary cancer.
Prof. Dr. Gontran Verset, an expert in digestive oncology from the Université Libre de Bruxelles, shares the latest findings from various studies presented in the poster discussion session on gastric,
During a recent update on cancer treatment, Prof. Dr. Hans Prenen, a digestive oncologist at the University Hospital of Antwerp, shared the latest data on various studies.
In-depth stories about GI
Prof Eric Van Cutsem and Prof Richard Finn explored the outcomes of the MORPHEUS-Liver study. This study was a phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and
Prof Dr George Lau presented an exploratory post hoc analysis derived from the phase 3 HIMALAYA study. This study focused on patients diagnosed with unresectable hepatocellular carcinoma (uHCC). The analysis
Prof Eric Van Cutsem and Prof Deborah Schrag discuss the PROSPECT study. This study is a randomized phase III trial that aims to compare neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy
GI poster selection
Prof Miriam Koopman presented the findings of the CAIRO-4 study. This study, conducted by the Dutch Colorectal Cancer Group, aimed to evaluate the potential advantages of upfront primary tumour resection
Dr Benedikt Westphalen addressed the question of whether both irinotecan and oxaliplatin are necessary in the first-line treatment for treatment-naïve metastatic pancreatic cancer. Additionally, the study aimed to determine if
Dr Floris Verheij presented the long-term results of the OPRA trial. The OPRA trial focused on patients with locally advanced rectal cancer and aimed to evaluate the effectiveness of total